Clinical

Dataset Information

0

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC


ABSTRACT: The objective is to compare the efficacy and safety of CAPOXIRI+BEV therapy versus FOLFOXIRI+BEV therapy as first-line therapy in patients with metastatic colorectal cancer (mCRC).

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2316883 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2181974 | ecrin-mdr-crc
| 2312043 | ecrin-mdr-crc
2023-07-20 | GSE232525 | GEO
| 2195502 | ecrin-mdr-crc
| 2535112 | ecrin-mdr-crc
| 2356077 | ecrin-mdr-crc
2024-07-17 | GSE261186 | GEO
2018-11-21 | GSE110785 | GEO
| 2023434 | ecrin-mdr-crc
2013-12-01 | GSE52735 | GEO